Second, the risk of ICB‐related pneumonitis for each combined therapy (chemotherapy, targeted therapy, CTLA‐4 blockade or radiotherapy) might vary due to distinct pharmacological mechanisms. The gene discussed is CTLA4; the disease is pneumonitis.